Genentech, Inc.
NEWS
What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting.
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or cardiovascular cavity. A 2017 study reported that the number of people affected by this rare cancer is between 2,400 - 2,800 individuals per year in the United States alone.
AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer.
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
The company, with sites in Seattle and South San Francisco, focuses on next-generation oncology therapeutics. It recently completed a portfolio review and decided to focus its energies and existing capital on G100 and abandoned its CMB305 program.
Two well-established pharma companies are expanding in two different U.S. cities. One city is known for the plethora of pharma and biotech jobs, while the other is in an area that might not immediately spring to mind when it comes to biotech hubs.
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
JOBS
IN THE PRESS